APAC Bovine Respiratory Disease Treatment Market

APAC Bovine Respiratory Disease Treatment Market Size (2022 to 2027)

The Asia Pacific Bovine Respiratory Disease Treatment Market was estimated at USD 7.63 million in 2022. It is further projected to reach USD 28.40 million by 2027, growing at a CAGR of 30.05% during the forecast period.  In the Asia Pacific region, China and India have greater cattle adoption and are expected to grow fast.

BRD is more than just a disease. It’s a respiratory disease complex that combines disease organisms with management and environmental stressors. There are several built-in stressors such as transition stress, feed changes, and environmental exposures. These stressors combine with disease organisms and advance into a complex that challenges an animal’s health. 

In the current scenario, cattle producers are trying to maximize the performance of each animal. Bovine respiratory disease (BRD) is a challenge to all cattle producers. There are many types of infectious agents involved. These agents not only cause severe pneumonia but also swollen, painful joints in calves.

This research report segmented and sub-segmented the Asia Pacific Bovine Respiratory Disease Treatment Market into the following categories:

By Treatment Type: 

• Anti-Infectious Agents
  • Antibiotics           
  • Sulfates    
• Anti-Parasiticides                 
• Bronchodilators                    
• Oral Rehydration Fluids                     
• Non-Steroidal Anti-Inflammatories               
• Mucolytics

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Notable companies leading the APAC Bovine Respiratory Disease Treatment Market are Zoetis Inc., Merck & Co. Inc., Bayer Corporation, Eli Lilly & Co, Merial S.A.S, Boehringer Ingelheim Vetmedica, Novartis Animal Health, Vibrac S.A., Ceva Sante Animale, and Vétoquinol S.A.